{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:08:23Z","timestamp":1789236503790,"version":"build-2803163510"},"reference-count":55,"publisher":"Zhejiang University Press","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1631\/jzus.b2400470","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T03:01:19Z","timestamp":1737342079000},"page":"26-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression","\u6c83\u66ff\u897f\u6c40\u8f85\u52a9\u6cbb\u7597\u53cc\u76f8\u6291\u90c1\u53d1\u4f5c\u7684\u4e34\u5e8a\u7597\u6548\u548c\u5b89\u5168\u6027"],"prefix":"10.1631","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2496-1887","authenticated-orcid":false,"given":"Chunxiao","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-0374","authenticated-orcid":false,"given":"Yaoyang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-1596","authenticated-orcid":false,"given":"Xuanwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-7558","authenticated-orcid":false,"given":"Jian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-0588","authenticated-orcid":false,"given":"Qingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-670X","authenticated-orcid":false,"given":"Shaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"3","key":"773_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14656566.2019.1695777","volume":"21","author":"Z Ali","year":"2020","unstructured":"Ali Z, Tegin C, El-Mallakh RS, 2020. Evaluating lurasidone as a treatment option for bipolar disorder. Expert Opin Pharmacother, 21(3):253\u2013260. https:\/\/doi.org\/10.1080\/14656566.2019.1695777","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"773_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269881116628440","volume":"30","author":"DS Baldwin","year":"2016","unstructured":"Baldwin DS, Chrones L, Florea I, et al., 2016. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol, 30(3):242\u2013252. https:\/\/doi.org\/10.1177\/0269881116628440","journal-title":"J Psychopharmacol"},{"issue":"9","key":"773_CR3","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"B Bang-Andersen","year":"2011","unstructured":"Bang-Andersen B, Ruhland T, J\u00f8rgensen M, et al., 2011. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem, 54(9): 3206\u20133221. https:\/\/doi.org\/10.1021\/jm101459g","journal-title":"J Med Chem"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","volume":"14","author":"A Berhan","year":"2014","unstructured":"Berhan A, Barker A, 2014. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry, 14:276. https:\/\/doi.org\/10.1186\/s12888-014-0276-x","journal-title":"BMC Psychiatry"},{"issue":"9","key":"773_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.euroneuro.2017.06.013","volume":"27","author":"JR Calabrese","year":"2017","unstructured":"Calabrese JR, Pikalov A, Streicher C, et al., 2017. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol, 27(9):865\u2013876. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"773_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","volume":"178","author":"JR Calabrese","year":"2021","unstructured":"Calabrese JR, Durgam S, Satlin A, et al., 2021. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry, 178(12):1098\u20131106. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20091339","journal-title":"Am J Psychiatry"},{"issue":"10","key":"773_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/14740338.2019.1651291","volume":"18","author":"E Cheniaux","year":"2019","unstructured":"Cheniaux E, Nardi AE, 2019. Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf, 18(10):893\u2013913. https:\/\/doi.org\/10.1080\/14740338.2019.1651291","journal-title":"Expert Opin Drug Saf"},{"issue":"10128","key":"773_CR8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, et al., 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391(10128):1357\u20131366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7","journal-title":"Lancet"},{"issue":"2","key":"773_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1590\/1516-4446-2012-1693","volume":"37","author":"AS Clemente","year":"2015","unstructured":"Clemente AS, Diniz BS, Nicolato R, et al., 2015. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry, 37(2):155\u2013161. https:\/\/doi.org\/10.1590\/1516-4446-2012-1693","journal-title":"Braz J Psychiatry"},{"issue":"9","key":"773_CR10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamapsychiatry.2013.1394","volume":"70","author":"C Crump","year":"2013","unstructured":"Crump C, Sundquist K, Winkleby MA, et al., 2013. Comor-bidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry, 70(9):931\u2013939. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.1394","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"773_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/1039856219839471","volume":"27","author":"G D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea G, de Ronchi D, Giaccotto L, et al., 2019. Vortioxetine treatment-emergent mania in the elderly: a case report. Australas Psychiatry, 27(4):413. https:\/\/doi.org\/10.1177\/1039856219839471","journal-title":"Australas Psychiatry"},{"issue":"5","key":"773_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14740338.2022.2019705","volume":"21","author":"J de Diego-Adelino","year":"2022","unstructured":"de Diego-Adelino J, Crespo JM, Mora F, et al., 2022. Vortiox-etine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf, 21(5):673\u2013690. https:\/\/doi.org\/10.1080\/14740338.2022.2019705","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"773_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaac.2017.10.006","volume":"56","author":"MP DelBello","year":"2017","unstructured":"DelBello MP, Goldman R, Phillips D, et al., 2017. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 56(12): 1015\u20131025. https:\/\/doi.org\/10.1016\/j.jaac.2017.10.006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jad.2021.05.043","volume":"292","author":"B Dell\u2019Osso","year":"2021","unstructured":"Dell\u2019Osso B, Arici C, Cafaro R, et al., 2021. Antidepressants in bipolar disorder: analysis of correlates overall, and in BD-I and BD-II subsamples. J Affect Disord, 292:352\u2013358. https:\/\/doi.org\/10.1016\/j.jad.2021.05.043","journal-title":"J Affect Disord"},{"issue":"8","key":"773_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/medicina55080403","volume":"55","author":"P Dome","year":"2019","unstructured":"Dome P, Rihmer Z, Gonda X, 2019. Suicide risk in bipolar disorder: a brief review. Medicina (Kaunas), 55(8):403. https:\/\/doi.org\/10.3390\/medicina55080403","journal-title":"Medicina (Kaunas)"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jad.2015.02.011","volume":"178","author":"A Forte","year":"2015","unstructured":"Forte A, Baldessarini RJ, Tondo L, et al., 2015. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord, 178:71\u201378. https:\/\/doi.org\/10.1016\/j.jad.2015.02.011","journal-title":"J Affect Disord"},{"issue":"3","key":"773_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jad.2011.04.043","volume":"138","author":"KN Fountoulakis","year":"2012","unstructured":"Fountoulakis KN, Kelsoe JR, Akiskal H, 2012. Receptor targets for antidepressant therapy in bipolar disorder: an overview. J Affect Disord, 138(3):222\u2013238. https:\/\/doi.org\/10.1016\/j.jad.2011.04.043","journal-title":"J Affect Disord"},{"key":"773_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2024.01.002","volume":"81","author":"KN Fountoulakis","year":"2024","unstructured":"Fountoulakis KN, Tohen M, Zarate CA, 2024. Pharmacody-namic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data. Eur Neuropsychopharmacol, 81:1\u20139. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.01.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"773_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1176\/appi.ajp.2008.08050746","volume":"166","author":"JF Goldberg","year":"2009","unstructured":"Goldberg JF, Perlis RH, Bowden CL, et al., 2009. Manic symptoms during depressive episodes in 1, 380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry, 166(2):173\u2013181. https:\/\/doi.org\/10.1176\/appi.ajp.2008.08050746","journal-title":"Am J Psychiatry"},{"issue":"10027","key":"773_CR20","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","volume":"387","author":"I Grande","year":"2016","unstructured":"Grande I, Berk M, Birmaher B, et al., 2016. Bipolar disorder. Lancet, 387(10027):1561\u20131572. https:\/\/doi.org\/10.1016\/S0140-6736(15)00241-X","journal-title":"Lancet"},{"issue":"5","key":"773_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","volume":"56","author":"WM Greenberg","year":"2017","unstructured":"Greenberg WM, Citrome L, 2017. Pharmacokinetics and phar-macodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet, 56(5):493\u2013503. https:\/\/doi.org\/10.1007\/s40262-016-0465-5","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"773_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, et al., 2010. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther, 334(1):171\u2013181. https:\/\/doi.org\/10.1124\/jpet.110.167346","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"773_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1017\/S1092852916000079","volume":"21","author":"A Kaltenboeck","year":"2016","unstructured":"Kaltenboeck A, Winkler D, Kasper S, 2016. Bipolar and related disorders in DSM-5 and ICD-10. CNS Spectr, 21(4): 318\u2013323. https:\/\/doi.org\/10.1017\/S1092852916000079","journal-title":"CNS Spectr"},{"issue":"12","key":"773_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/pcn.13137","volume":"74","author":"T Kato","year":"2020","unstructured":"Kato T, Ishigooka J, Miyajima M, et al., 2020. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci, 74(12):635\u2013644. https:\/\/doi.org\/10.1111\/pcn.13137","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"773_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/da.22479","volume":"33","author":"TA Ketter","year":"2016","unstructured":"Ketter TA, Sarma K, Silva R, et al., 2016. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety, 33(5):424\u2013434. https:\/\/doi.org\/10.1002\/da.22479","journal-title":"Depress Anxiety"},{"issue":"2","key":"773_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1176\/appi.ajp.163.2.232","volume":"163","author":"GS Leverich","year":"2006","unstructured":"Leverich GS, Altshuler LL, Frye MA, et al., 2006. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry, 163(2):232\u2013239. https:\/\/doi.org\/10.1176\/appi.ajp.163.2.232","journal-title":"Am J Psychiatry"},{"issue":"6","key":"773_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ijnp\/pyad018","volume":"26","author":"ZJ Li","year":"2023","unstructured":"Li ZJ, Liu SH, Wu QX, et al., 2023. Effectiveness and safety of vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and metaanalysis. Int J Neuropsychopharmacol, 26(6):373\u2013384. https:\/\/doi.org\/10.1093\/ijnp\/pyad018","journal-title":"Int J Neuropsychopharmacol"},{"key":"773_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jad.2017.07.023","volume":"223","author":"BS Liu","year":"2017","unstructured":"Liu BS, Zhang Y, Fang H, et al., 2017. Efficacy and safety of long-term antidepressant treatment for bipolar disorders\u2014 a meta-analysis of randomized controlled trials. J Affect Disord, 223:41\u201348. https:\/\/doi.org\/10.1016\/j.jad.2017.07.023","journal-title":"J Affect Disord"},{"issue":"2","key":"773_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, et al., 2014a. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry, 171(2):160\u2013168. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13070984","journal-title":"Am J Psychiatry"},{"issue":"2","key":"773_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, et al., 2014b. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry, 171(2):169\u2013177. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13070985","journal-title":"Am J Psychiatry"},{"issue":"12","key":"773_CR31","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","volume":"3","author":"A McGirr","year":"2016","unstructured":"McGirr A, V\u00f6hringer PA, Ghaemi SN, et al., 2016. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry, 3(12):1138\u20131146. https:\/\/doi.org\/10.1016\/S2215-0366(16)30264-4","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"773_CR32","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","volume":"35","author":"RS McIntyre","year":"2019","unstructured":"McIntyre RS, Calabrese JR, 2019. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin, 35(11):1993\u20132005. https:\/\/doi.org\/10.1080\/03007995.2019.1636017","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"773_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1017\/S1092852913000746","volume":"18","author":"RS McIntyre","year":"2013","unstructured":"McIntyre RS, Cha DS, Kim RD, et al., 2013. A review of FDA-approved treatment options in bipolar depression. CNS Spectr, 18(Suppl 1):4\u201320. https:\/\/doi.org\/10.1017\/S1092852913000746","journal-title":"CNS Spectr"},{"issue":"4","key":"773_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1017\/S1092852919001287","volume":"25","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Suppes T, Earley W, et al., 2020. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr, 25(4):502\u2013510. https:\/\/doi.org\/10.1017\/S1092852919001287","journal-title":"CNS Spectr"},{"issue":"9","key":"773_CR35","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, et al., 2011. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry, 168(9):957\u2013967. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10060907","journal-title":"Am J Psychiatry"},{"issue":"1Pt2","key":"773_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1399-5618.2007.00559.x","volume":"10","author":"PB Mitchell","year":"2008","unstructured":"Mitchell PB, Goodwin GM, Johnson GF, et al., 2008. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord, 10(1Pt 2):144\u2013152. https:\/\/doi.org\/10.1111\/j.1399-5618.2007.00559.x","journal-title":"Bipolar Disord"},{"issue":"4","key":"773_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M, 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry, 134(4): 382\u2013389. https:\/\/doi.org\/10.1192\/bjp.134.4.382","journal-title":"Br J Psychiatry"},{"issue":"3","key":"773_CR38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1124\/jpet.111.189068","volume":"340","author":"A M\u00f8rk","year":"2012","unstructured":"M\u00f8rk A, Pehrson A, Brennum LT, et al., 2012. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther, 340(3):666\u2013675. https:\/\/doi.org\/10.1124\/jpet.111.189068","journal-title":"J Pharmacol Exp Ther"},{"key":"773_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.euroneuro.2021.04.009","volume":"47","author":"I Pacchiarotti","year":"2021","unstructured":"Pacchiarotti I, Verdolini N, 2021. Antidepressants in bipolar II depression: yes and no. Eur Neuropsychopharmacol, 47: 48\u201350. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.04.009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"773_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1503\/jpn.140120","volume":"40","author":"CU Pae","year":"2015","unstructured":"Pae CU, Wang SM, Han CS, et al., 2015. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci, 40(3): 174\u2013186. https:\/\/doi.org\/10.1503\/jpn.140120","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"773_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.psc.2015.09.001","volume":"39","author":"RM Post","year":"2016","unstructured":"Post RM, 2016. Treatment of bipolar depression: evolving recommendations. Psychiatr Clin North Am, 39(1):11\u201333. https:\/\/doi.org\/10.1016\/j.psc.2015.09.001","journal-title":"Psychiatr Clin North Am"},{"issue":"3","key":"773_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/appy.12186","volume":"8","author":"RJ Roberts","year":"2016","unstructured":"Roberts RJ, Lohano KK, El-Mallakh RS, 2016. Antipsychotics as antidepressants. Asia Pac Psychiatry, 8(3):179\u2013188. https:\/\/doi.org\/10.1111\/appy.12186","journal-title":"Asia Pac Psychiatry"},{"issue":"Suppl 20","key":"773_CR43","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al., 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 59(Suppl 20):22\u201333.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"773_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4088\/JCP.09r05385gre","volume":"72","author":"MM Sidor","year":"2011","unstructured":"Sidor MM, Macqueen GM, 2011. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry, 72(2):156\u2013167. https:\/\/doi.org\/10.4088\/JCP.09r05385gre","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"773_CR45","doi-asserted-by":"publisher","first-page":"509","DOI":"10.12740\/PP\/OnlineFirst\/132962","volume":"56","author":"M Siwek","year":"2022","unstructured":"Siwek M, Chrobak AA, Soltys Z, et al., 2022. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression. Psychiatr Pol, 56(3):509\u2013522. https:\/\/doi.org\/10.12740\/PP\/OnlineFirst\/132962","journal-title":"Psychiatr Pol"},{"issue":"1","key":"773_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1590\/1516-4446-2016-2113","volume":"39","author":"G Sobreira","year":"2017","unstructured":"Sobreira G, Oliveira J, Brissos S, 2017. Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder. Braz J Psychiatry, 39(1):86. https:\/\/doi.org\/10.1590\/1516-4446-2016-2113","journal-title":"Braz J Psychiatry"},{"key":"773_CR47","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2147\/DDDT.S63779","volume":"8","author":"S Suttajit","year":"2014","unstructured":"Suttajit S, Srisurapanont M, Maneeton N, et al., 2014. Que-tiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther, 8:827\u2013838. https:\/\/doi.org\/10.2147\/DDDT.S63779","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"773_CR48","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/JCP.0000000000001590","volume":"42","author":"Y Takaesu","year":"2022","unstructured":"Takaesu Y, Takeshima M, Watanabe K, 2022. Effectiveness and tolerability of lurasidone for bipolar types I and II and other specified bipolar depression: a 12-week observational study. J Clin Psychopharmacol, 42(5):485\u2013488. https:\/\/doi.org\/10.1097\/JCP.0000000000001590","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"773_CR49","doi-asserted-by":"publisher","first-page":"e2308","DOI":"10.1002\/brb3.2308","volume":"11","author":"T Terao","year":"2021","unstructured":"Terao T, 2021. Neglected but not negligible aspects of antide-pressants and their availability in bipolar depression. Brain Behav, 11(8):e2308. https:\/\/doi.org\/10.1002\/brb3.2308","journal-title":"Brain Behav"},{"issue":"5","key":"773_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/acps.12023","volume":"127","author":"L Tondo","year":"2013","unstructured":"Tondo L, Baldessarini RJ, V\u00e1zquez G, et al., 2013. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand, 127(5):355\u2013364. https:\/\/doi.org\/10.1111\/acps.12023","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"773_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00213-013-3103-z","volume":"229","author":"DF Wong","year":"2013","unstructured":"Wong DF, Kuwabara H, Bra\u0161i\u0107 JR, et al., 2013. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl), 229(2):245\u2013252. https:\/\/doi.org\/10.1007\/s00213-013-3103-z","journal-title":"Psychopharmacology (Berl)"},{"key":"773_CR52","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2147\/NDT.S245166","volume":"16","author":"N Yalin","year":"2020","unstructured":"Yalin N, Young AH, 2020. Pharmacological treatment of bipolar depression: what are the current and emerging options? Neuropsychiatr Dis Treat, 16:1459\u20131472. https:\/\/doi.org\/10.2147\/NDT.S245166","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"773_CR53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al., 2018. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 20(2):97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609","journal-title":"Bipolar Disord"},{"issue":"2","key":"773_CR54","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41397-019-0101-5","volume":"20","author":"A Yoshikawa","year":"2020","unstructured":"Yoshikawa A, Li J, Meltzer HY, 2020. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other an-tipsychotic drugs. Pharmacogenomics J, 20(2):260\u2013270. https:\/\/doi.org\/10.1038\/s41397-019-0101-5","journal-title":"Pharmacogenomics J"},{"key":"773_CR55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, et al., 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry, 133:429\u2013435. https:\/\/doi.org\/10.1192\/bjp.133.5.429","journal-title":"Br J Psychiatry"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2400470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2400470\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2400470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T03:02:53Z","timestamp":1745982173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2400470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2400470","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chunxiao DAI, Yaoyang FU, Xuanwei LI, Meihua LIN, Yinbo LI, Xiao LI, Keke HUANG, Chengcheng ZHOU, Jian XIE, Qingwei ZHAO, and Shaohua HU declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This study was approved by the Clinical Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, China (Approval No. IIT20210111C-R1), and registered on the ClinicalTrials. gov (Clinicaltrials. gov identifier: NCT05481957). Informed consent was obtained from all patients and their families.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}